KRAS and non-small cell lung carcinoma: In phase III trials, PD‐1 antibody (nivolumab) or PD‐L1 antibody (atezolizumab) could improve survival to varying degrees in KRAS‐mutant chemorefractory NSCLC patients.51, 52